



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product: APC Anti-Human CD19

Other Name: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12.

Cat. Ref: 19A1-100T

Reagent provided: 100 test (20µl / test*)


Description: Mouse Monoclonal Anti-Human CD19, is recommended for use in flow cytometry for identification of human B cells associated approximately with 10% of peripheral blood lymphocytes 95,000 M.W. surface antigen. The conjugate is provided in aqueous buffered solution containing protein stabilizer, and ≤0.09% sodium Azide

Clone: A3-B1

Isotype: IgG2a

Fluorochrome: APC (Ex-Max: 650 nm/Em-Max: 660). The fluorophore is excited with a dye laser (600 nm) or a helium-neon (HeNe) laser (633 nm). It is recommended to use a 660/20 band pass filter detector-equipped flow cytometer.

* see Title



INTENDED PURPOSE.

IMMUNOSTEP Anti-Human CD19 APC is fluorochrome conjugated monoclonal antibody for identifying and enumerating CD19+ lymphocytes by flow cytometry.

TECHNICAL SUMMARY.

Reactivity: The monoclonal antibody is directed against the CD19- antigen (B4-antigen), which is expressed on human B lymphocytes. The monoclonal antibody is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells. Plasma cells were found to be negative. The monoclonal antibody does not react with other haemopoietic cells. The monoclonal antibody also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Virtually all non T-ALL, B-CLL and B-cell lymphomas were found to be positive, myeloma cells were found to be negative.

Specificity: CD19 is a 90-95 Kd MW lymphocyte surface antigen identified by monoclonal antibodies belonging to the CD19 cluster. CD19 is expressed from the earliest stages of B-progenitor development and on all peripheral B cells including germinal centre B cells, all B cell lines tested and B cell leukaemias tested. The antigen is lost on B cell maturation to plasma cells.

CLINICAL RELEVANCE

The monoclonal antibody may be used to identify and enumerate CD19+ B lymphocytes in human peripheral blood. This may be valuable, in combination with other indicators, for the diagnosis or prognosis of some immunodeficiency diseases, including agammaglobulinemia, severe combined immunodeficiency disease (SCID) and common variable immunodeficiency disease (CVID) which are all reported to demonstrate reduced numbers of circulating B lymphocytes. The reagent may also be of value in determining the lineage of malignant lymphoid cells in cases of chronic and acute leukaemia and lymphoma, with the great majority of B cell malignancies expressing CD19.

PRINCIPLES OF THE TEST.

Immunostep CD19 APC monoclonal antibodies bind to the surface of cells that express the CD19 antigen. To identify these cells, peripheral blood leucocytes are incubated with the antibodies and red blood cells are lysed before washing to remove unbound antibodies. After that cells are analysed by flow cytometry with a 633 nm laser.

REAGENTS.

Cluster Designation:	CD19
Clone:	A3-B1
Isotype:	IgG2a
Species:	Mouse
Composition:	IgG2a heavy chain Kappa light chain
Source:	Hybridome Cells
Method of Purification:	Affinity chromatography
Fluorochrome:	Allophycocyanin (APC) Excitation wavelength 633 nm Emission wavelength 664 nm
Molar composition:	APC/protein 1±0.5
Reagents contents:	2 ml vial containing monoclonal antibody for 100 tests. The conjugate is provided in aqueous buffered solution containing protein stabilizer, and ≤0.09% sodium Azide
Reagent preparation:	Ready to use.

1. STATEMENTS, SETTINGS AND WARNINGS.

- Reagents contain sodium azide. Sodium azide under acid conditions yields hydrazoic acid, an extremely toxic compound. Azide compounds should be diluted with running water before being discarded. These conditions are recommended to avoid deposits in plumbing where explosive conditions may develop.
- Light exposure should be avoided. Use dim light during handling, incubation with cells and prior to analysis.
- Do not pipet by mouth.
- Samples should be handled as if capable of transmitting infection. Appropriate disposal methods should be used.
- The sample preparation procedure employs a fixative (formaldehyde). Contact is to be avoided with skin or mucous membranes.
- Do not use antibodies beyond the stated expiration dates of the products.
- Deviations from the recommended procedure enclosed within this product insert may invalidate the results of testing.
- FOR IN VITRO DIAGNOSTIC USE
- For professional use only.

2. APPROPRIATE STORAGE CONDITIONS.

- Keep in dark place at 2-8°C. DO NOT FREEZE.

3. EVIDENCE OF DETERIORATION.

- Reagents should not be used if any evidence of deterioration or substantial loss of reactivity is observed. For more information, please contact with our technical service: tech@immunostep.com
- The normal appearance of the APC-conjugated monoclonal antibody is a clear blue liquid.

4. SPECIMEN COLLECTION.

Collect venous blood samples into blood collection tubes using an appropriate anticoagulant (EDTA or heparin). For optimal results the sample should be processed within 6 hours of venipuncture. EDTA, ACD or heparin may be used if the blood sample is processed for analysis within 30 hours of venipuncture. ACD or heparin, but not EDTA, may be used if the sample is not processed within 30 hours of venipuncture. Samples that cannot be processed within 48 hours should be discarded.

If venous blood samples are collected into ACD for flow cytometric analysis, a separate venous blood sample should be collected into EDTA if a CBC is required.

Unstained anticoagulated blood should be retained at 20- 25°C prior to sample processing. Blood samples that are hemolyzed, clotted or appear to be lipemic, discoloured or to contain interfering substances should be discarded.

Refer to "*Standard Procedures for the Collection of Diagnostic Blood Specimens*" published by the National Committee for Clinical Laboratory Standards (NCCLS) for additional information on the collection of blood specimens.

5. SAMPLE PREPARATION: Staining Cell Surface Antigens for Flow Cytometry Protocol

1. Add 20 µL of CD19 APC to a 12 x 75 mm polystyrene test tube. The 20 µL is a guideline only; the optimal volume should be determined by the individual laboratory
2. Transfer 100 µL of anticoagulated (EDTA) blood or the study sample (10^6 cells) and mix gently with a vortex mixer (until the process moment, keep in cold). Determine cell viability using Trypan Blue or propidium iodide. If the cell viability is not at least 85%, the blood sample should be discarded.
3. The recommended negative control is a non-reactive APC-conjugated antibody of the same isotype.
4. Incubate in the dark at room temperature (20-25 °C) for 15 minutes or at 4 °C for 30 minutes.
5. Add Lysing Solution according to the manufacturer's directions to each sample and mix gently with a vortex mixer.
6. Centrifuge at 540g for 5 minutes. Gently aspirate the supernatant without disturbing the cell pellet and discard it leaving approximately 50 µL of fluid.
7. Add 2 mL 0.01 mol/L PBS (It better that it containing 0,5 % bovine serum albumin) and resuspend the cells. Mix well.
8. Centrifuge at 540g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µL of fluid.
9. Resuspend pellet in an appropriate fluid for flow cytometry, e.g. 0.3 mL PBS + 0,5 % BSA.

Analyse on a flow cytometer or store at 2-8 °C in the dark until analysis. Samples can be run up to 3 hours after lysis.

6. MATERIALS REQUIRED BUT NOT SUPPLIED.

Isotype control reagents:	Mouse IgG2a: APC
Leucocyte gating reagent:	Mouse anti-human CD45/CD14
Serofuge or equivalent centrifuge	
12 x 75 mm polypropylene centrifuge tubes	
Micropipette capable of dispensing 5 µl, 20 µl, 100 µl, and 500 µl volumes	
Blood collection tubes with anticoagulant	
Phosphate buffered saline (PBS)	
Trypan Blue or propidium iodide, 0.25% (w/v) in PBS for the determination of cell viability	
Lysing Solution	
Fixing Solution	


Flow cytometer:	Becton Dickinson FACSCalibur™, Coulter Profile or equivalent 488 nm ion argon laser or 561-nm (Yellow-Green) laser, 556 LP filter, 585/42 or 575/26 detector-equipped and appropriate computer hardware and software.
-----------------	---

7. INTERPRETATION OF RESULTS.

FLOW CYTOMETRY

Analyze antibody-stained cells on an appropriate flow cytometer analyzer according to the manufacturer instructions. The right angle light scatter or other scatter (SSC) versus forward angle light scatter (FSC) is collected to reveal the lymphocyte cell cluster. A gate is drawn for the lymphocyte cluster (lymphocyte bitmap). The fluorescence attributable to the APC-conjugated monoclonal antibody is collected, and the percentage of antibody-stained T lymphocytes is determined.

An appropriate APC-conjugated isotypic control of the same heavy chain immunoglobulin class and antibody concentration must be used to estimate and correct for non-specific binding to lymphocytes. An analysis region is set to exclude background fluorescence and to include positively stained cells. The following histograms are representative of cells.



The histogram is biparametric representations (Side Scatter versus Fluorescence Intensity) of a lysate mouse whole blood sample. Mouse peripheral blood lymphocytes were stained with CD19 APC and CD45 PerCP.

Cells were analyzed on a FACS Aria II (Becton Dickinson, San Jose, CA) flow cytometer, using BD FACSDiva software.

FOR MORE INFORMATION, PLEASE VISIT OUR WEBSITE: www.immunostep.com

8. QUALITY CONTROL PROCEDURES.

Non-specific fluorescence identified by the FITC conjugated isotypic control is usually less than 2% in normal individuals. Non-specific fluorescence identified by the PE and APC conjugated isotypic controls are usually less than 4% in normal individuals. If the background level exceeds these values, test results may be in error. Increased non-specific fluorescence may be seen in some disease states.

A blood sample from each normal and abnormal donor should be stained with the CD45 Pan-lymphocyte and CD14 Pan-monocyte monoclonal antibodies. When used in combination, these reagents assist in identifying the lymphocyte analysis region, and distinguish lymphocytes from monocytes, granulocytes and unlysed or nucleated red cells and cellular debris.

A blood sample from a healthy normal donor should be analyzed as a positive control on a daily basis or as frequently as needed to ensure proper laboratory working conditions. Each laboratory should establish their own normal ranges, since values obtained from normal samples may vary from laboratory to laboratory.

An appropriate isotype control should be used as a negative control with each patient sample to identify non-specific Fc binding to lymphocytes. An analysis region should be set to exclude the non-

specific fluorescence identified by the isotypic control, and to include the brighter fluorescence of the lymphocyte population that is identified by the specific antibody.

Refer to the appropriate flow cytometer instrument manuals and other available references for recommended instrument calibration procedures.

9. LIMITATIONS OF THE PROCEDURE.

1. Incubation of antibody with cells for other than the recommended time and temperature may result in capping or loss of antigenic determinants from the cell surface.
2. The values obtained from normal individuals may vary from laboratory to laboratory; therefore, it is recommended that each laboratory establish its own normal range.
3. Abnormal cells or cell lines may have a higher antigen density than normal cells. This could, in some cases, require the use of a larger quantity of monoclonal antibody than is indicated in the procedures for Sample Preparation.
4. Blood samples from abnormal donors may not always show abnormal values for the percentage of lymphocytes stained with a given monoclonal antibody. Results obtained by flow cytometric analysis should be considered in combination with results from other diagnostic procedures.
5. When using the whole blood method, red blood cells found in some abnormal donors, as well as nucleated red cells found in normal and abnormal donors may be resistant to lysis by lysing solutions. Longer red cell lysis periods may be needed to avoid the inclusion of unlysed red cells in the lymphocyte gated region.
6. Blood samples should not be refrigerated or retained at ambient temperature for an extensive period (longer than 24-30 hours) prior to incubating with monoclonal antibodies.
7. Accurate results with flow cytometric procedures depend on correct alignment and calibration of the laser, as well as proper gate settings.
8. Due to an unacceptable variance among the different laboratory methods for determining absolute lymphocyte counts, an assessment of the accuracy of the method used is necessary.
9. All results need to be interpreted in the context of clinical features, complete immunophenotype and cell morphology, taking due account of samples containing a mixture of normal and neoplastic cells.

10. REFERENCE VALUES.

The cellular elements of human Bone Marrow include lymphocytes, monocytes, granulocytes, red blood cells and platelets.

Nucleated cells Percentage in the Bone Marrow

Cell type	Percentage
Progranulocytes	56,7
Neutrophils	53,6
Myeloblasts	0,9
Promyeloblasts	3,3
Promyelocytes	12,7
Metamyelocytes	15,9
Eosinophils	3,1
Basophils	<0,1
Proerythrocyte	25,6
Proerythblasts	0,6
Basophil Erythroblast	1,4
Polycromatic Erythroblast	21,6
Ortocromatic Erythroblast	2
Megakaryocytes	<0,2
Lymphocytes	16,2
Plasma cells	2,3
Reticular cells	0,4

Normal human peripheral blood lymphocytes 20-47% (n=150% confidence interval)

Nucleated cells Percentage in Peripheral Blood of a Normal Patient

Cell type	Percentage	Number of event.
Red Blood Count		3,8 - 5,6 X10 ⁹ /μL
Platelets		150 - 450 X10 ³ /μL
White Blood Count (WBC)		4.3 - 10.0 X10 ³ /μL
Neutrophils	57 – 67 %	1,5 - 7.0 X10 ³ /μL
Lymphocytes*	25 – 33 %	1.0 - 4.8 X10 ³ /μL
T cell	56 – 82 % of lymphocytes	
T cell CD4+	60 % of T cells	
T cell CD8+	40 % of T cells	
Cell NK+	6 – 33 of lymphocytes	
B cell	7.7 – 22 of lymphocytes	
Monocytes	3 – 7 %	0.28 - 0.8 X10 ³ /μL
Eosinophils	1 – 3 %	0.05 – 0,25 X10 ³ /μL
Basophils	0 – 0,075 %	0,015 – 0,05 X10 ³ /μL
Reticulocyte	0,5 – 1,5 % of total Red Blood Cell	

Expected values for pediatrics and adolescents have not been established. The values obtained from normal individuals may vary from laboratory to laboratory; therefore, it is recommended that each laboratory establish its own normal range.

11. PERFORMANCE CHARACTERISTICS.

SPECIFICITY

CD19 is expressed on B lymphocytes cells. To evaluate the reagent's specificity (cross-reactivity with other cell populations), 10 blood samples from healthy donors were studied, stained with an adequate isotype control and the MAb to study.

Blood samples obtained from healthy normal donors of Caucasian were stained with Immunostep CD19 APC monoclonal antibody. Cells contained in platelets, erythrocytes, monocytes, lymphocyte and non-specific fluorescence identified by the APC-conjugated isotypic control IgG2a into CD19+ lymphocyte region were selected for analysis. Blood samples were processed by a Staining Cell Surface Antigens for Flow Cytometry Protocol described in Section 5.

The results obtained are shown in the following table:

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
% Isotype control	10	,00	,07	,0310	,02025
% Platelets	10	,00	,01	,0030	,00483
% Erythrocytes	10	,00	,02	,0040	,00699
% T Lymphocyte	10	,00	,06	,0320	,02098
% Monocytes	10	,00	,05	,0160	,01838
Valid N (listwise)	10				

SENSIBILITY

Sensitivity of the Immunostep CD19 APC monoclonal antibody was determined by staining as positive the Ramos cell line and as negative the Jurkat cell line. Cells were mixed in different proportions with a constant final number of 1×10^6 cells to achieve different cell ratios from 0% positive cells to 100%.

Thereafter cells were incubated with the antibody according to the recommended amount for 15 minutes. Finally the cells were washed according to standard protocol. A linear regression between the expected values and the observed values was calculated.


To determine the consistency of the conjugated monoclonal antibody as opposed to small variations (but deliberate). It provides an indication of its reliability during its normal use.

Model Summary

Model	R	R Square	Adjusted R Square	Std. Error of the Estimate
1	,998 ^a	,996	,995	2,38383

a. Predictors: (Constant), % Expected

To determine the consistency of the conjugated monoclonal antibody as opposed to small variations (but deliberate). It provides an indication of its reliability during its normal use.



The results show an excellent correlation between the results obtained and expected based on the dilution used. CD19 APC sensibility was demonstrated from 1×10^5 to 1×10^6 cells in 1×10^6 total cells.

REPRODUCIBILITY

Reproducibility for the Immunostep CD19 APC-conjugated monoclonal antibodies was determined by performing 10 replicated determinations of each antibody in each of three ranges of lymphocytes; high, medium and low. Thus, a total of 30 determinations were performed. In this manner, reproducibility was demonstrated throughout the entire measuring range.

The 10 determinations for each range were performed by the staining, processing and analysis of 10 separate samples. Lymphocytes CD19+ were selected for the analysis of percent cells stained in each of the three ranges.

To perform this study, anticoagulated blood was obtained from three different donors expressing a high, medium and low percentage of Lymphocytes.

Descriptive Statistics

Range	N		Minimum	Maximum	Mean	Std. Deviation
	Percentage	Valid N (listwise)	Percentage	Percentage	Percentage	Percentage
High	9	9	1,93	2,74	2,2256	,29896
Medium	10	10	1,74	2,02	1,8670	,10339
Low	10	10	,56	,75	,6680	,05978

*Note: Data analyzed with SPSS for Windows 11.0.1

TITLE

Title for the Immunostep CD19 APC-conjugated monoclonal antibodies was determined by performing 3 sample with different dilutions and check nonspecific staining and specific staining of normal peripheral blood from healthy donor according to the protocol shown in item 5.

Quantity (μg)	N° of cells	% (in 1×10^6 cells)
0,125	Up $4,80 \times 10^4$	4,80 %
0,2	Up $7,68 \times 10^4$	7,68 %
0,5	Up $1,92 \times 10^5$	19,2%
1	Up $3,84 \times 10^5$	38,42%

12. BIBLIOGRAPHY.

1. A. Orfao, J. Almeida, M.L. Sánchez, F.M. Sánchez-Guijo, C. Vallejo, M.C. López-Berges, M.A. García-Marcos, M.J. Moro, J.F. San Miguel. Incidence of aberrant phenotypes in a large series of B-cell chronic lymphoproliferative disorders, implication for minimal residual disease.
2. Sato S, Tedder TF. BC3. CD19 workshop panel report. In: Kishimoto T, Kikutani H, von dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, et al., editors. Leukocyte typing VI. White cell differentiation antigens. Proceedings of the 6th International Workshop and Conference; 1996 Nov 10-14; Kobe, Japan. New York, London: Garland Publishing Inc.; 1997. p. 133-5.
3. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry 2001;46:23-7.
4. Sato S, Tedder TF. CD guide. CD19. In: Kishimoto T, Kikutani H, von dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, et al., editors. Leukocyte typing VI. White cell differentiation antigens. Proceedings of the 6th International Workshop and Conference; 1996 Nov 10-14; Kobe, Japan. New York, London: Garland Publishing Inc.; 1997. p. 764-5.
5. Leong AS-Y, Cooper K, Leong FJW-M. Manual of diagnostic antibodies for immunohistology. London: Oxford University Press; 1999. p. 67-8.
6. Pezzutto A, Dörken B, Feller A, Moldenhauer G, Schwartz R, Wernet P, et al. HD37 monoclonal antibody: a useful reagent for further characterization of "non-T, non-B" lymphoid malignancies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, editors. Leukocyte typing II. Proceedings of the 2nd International Workshop on Human Leukocyte Differentiation Antigens; 1984 Sept 17-20; Boston, USA. New York, Berlin, Heidelberg, Tokyo: Springer-Verlag; 1986. Volume 2. p. 391-402.
7. Nadler LM. B cell/leukemia panel workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, editors. Leukocyte typing II. Proceedings of the 2nd International Workshop on Human Leukocyte Differentiation Antigens; 1984 Sept 17-20; Boston, USA. New York, Berlin, Heidelberg, Tokyo: Springer-Verlag; 1986. Volume 2. p. 3-43.